Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin‐naive individuals with type 2 diabetes mellitus. Issue 12 (22nd July 2018)

• Record Type: Journal Article
• Authors: Frier, Brian M.; Landgraf, Wolfgang; Zhang, Mei; Bolli, Geremia B.; Owens, David R.
• Is Part Of: Diabetes, obesity & metabolism. Volume 20:Issue 12(2018)
• Page Start: 2894
• Page End: 2898
• Publication Date: 2018-07-22
• Subjects: clinical trial -- C‐peptide -- hypoglycaemia -- insulin glargine -- insulin initiation -- type 2 diabetes mellitus; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.13450
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract : Patient characteristics associated with hypoglycaemia frequency during insulin glargine 100 U/mL (Gla‐100) titration and clinical outcomes at Week 24 were examined using participant‐level data from 16 treat‐to‐target trials involving individuals with type 2 diabetes mellitus who were inadequately controlled with oral antidiabetes drugs and were initiating Gla‐100 (n = 3549). Hypoglycaemia (plasma glucose <3.9 mmol/L or severe) during the first 8 weeks of titration was stratified by number of events (0, 1‐3 and ≥4), resulting in 72.5%, 20.6% and 6.9% of participants in each group, respectively. Changes in glycaemia, body weight and insulin dose from baseline to Weeks 12 and 24 were analysed. Hypoglycaemia was more common in participants with lower BMI and fasting C‐peptide, and in those undergoing sulfonylurea treatment. Glycaemic outcomes at Week 24 were similar in each hypoglycaemia group, despite the fact that the Week 24 mean daily dose and dose increase for Gla‐100 were highest in participants without hypoglycaemia and were lowest in those experiencing ≥4 events. The risk of hypoglycaemia during Gla‐100 titration depends mainly on patient characteristics and on sulfonylurea use and may delay dose titration, which apparently has little effect on short‐term glycaemic control in a clinical trial setting.